Florida States' Largest Cannabis Company
"Trulieve is the largest cannabis company in the state of Florida. We have over seventeen hundred employees currently. We're manufacturing over 80 tho …

27 Brick & Mortar Locations
"Trulieve is the largest cannabis company in the state of Florida. We have over seventeen hundred employees currently. We're manufacturing over 80 thousand products a week to distribute to our 27 brick and mortar locations. The winners in the cannabis space are going to be those companies that can have authentic relationships with their customers." - Kim Rivers, CEO of Trulieve Cannabis Corp.
Trulieve is the first and leading medical cannabis company in the state of Florida, the third most populous state in the United States. Its vertically-integrated "seed-to-sale" operation has approximately 65% of the Florida market. With a patient base that grows approximately 10% month-to-month, it is poised for growth in this attractive market. Trulieve boasts over 150 SKUs and is constantly adding new, fresh, and exciting items to its product line. Its widespread dispensary network and large delivery fleet provides important, much-needed access to thousands of patients every day throughout the state.
Trulieve is committed to growing its dispensary footprint in the state, constantly identifying new locations that will bring Trulieve closer to patients throughout the state, allowing many more people to have easier access to the medicine they need. Its first mover advantage in the state provides numerous benefits, including brand recognition and media attention. Strong financial performance, driven by sales to a loyal and dedicated group of patients affectionately called Trulievers, positions the company's commitment to continue its pattern of growth.
For more information on Trulieve Cannabis Corp. (TRUL:CSE) please fill out the form below.
Latest Articles
Hot Companies
You might also like

Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine
Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.




.jpg)